Abstract
Premature ovarian failure and infertility are long-term consequences of chemotherapy in young women. Because primordial follicular cells in the ovary cannot regenerate, destruction of these cells results in ovarian dysfunction and premature ovarian failure. Histologic studies of chemotherapy-induced ovarian damage showed loss of primordial follicles and ovarian volume (1). Paclitaxel is an anticancer agent widely used in patients with carcinoma of the ovary, breast, and lung. In addition, promising results have been reported in patients with germ cell tumors and non-Hodgkin lymphomas, which occur frequently in young patients. Paclitaxel damages healthy mature oocytes (2) and affects short-term reproductive potential in a dose-dependent manner (3). However, a search of the MEDLINE database of the U.S. National Library of Medicine (1980 to 2000) found no study that evaluated the potential effect of paclitaxel on the primordial follicle reserve in healthy ovaries. The aim of our study was to evaluate the dose-related effects of paclitaxel on primordial follicle reserve in young mice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
